A biotech company focused on short-duration psychedelic-assisted therapies for mental health conditions announced positive top-line results from the first placebo-controlled efficacy study exploring a short-duration psychedelic for the treatment of major depressive disorder.

The drug was being tested in combination with androgen deprivation therapy and Xtandi, made by Pfizer Inc and Astellas Pharma Inc., in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

Findings from the pivotal Phase III NAPOLI 3 trial show Ipsen’s Onivyde (irinotecan liposome injection), when used as part of the investigational NALIRIFOX regimen, boosted overall survival in metastatic pancreatic ductal adenocarcinoma, the company announced Friday.

Sinopharm, now the China distributor of Merck & Co’s COVID-19 antiviral treatment molnupiravir, said its biotech unit received clinical trial approval from the National Medical Products Administration.

According to data from the IMbrave150 study, the drug combo is the first treatment option in over a decade to confer significant overall survival benefit over standard of care in unresectable hepatocellular carcinoma.

Junshi Biosciences’ Neotorch is the world’s first registered Phase III immuno-oncology trial for lung cancer to post positive EFS (event-free survival) data.

Moderna announced positive topline results from a Phase III trial with older adults and a vaccine candidate aimed at preventing respiratory syncytial virus.

The trial involved administering two different types of a shot that uses a cold-causing virus to deliver genetic code of HIV, spread over four vaccination visits in a year. J&J used a similar technology for its COVID-19 vaccine.

Ocugen Inc. said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd. met the main goals of a trial in the United States.

Galmed announces positive late-stage results in biopsy-proven NASH patients.